Clinical Trial Search

Primary: Annualized Relapse Rate (ARR) — 0.091; 0.178 relapses per participant-years — p=0.0022

Primary: Annualized Relapse Rate (ARR) — 0.076; 0.188 relapses per participant-years — p=<0.0001

Primary: Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening…

Primary: Mean Overall Response Score (ORS) at Week 52 — 0.04; -0.17; -0.17 score on a scale

Primary: Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16 — 0.9; 3.0 lesions — p=<0.001

Primary: Percentage of Relapse-free RMS Subjects — 66.3 percentage of subjects

Primary: Change From Baseline to Month 6 in CD4+ Naive T Cells (CCR7+ CD45RA+) — 404.4; 3.4; 7.6; 4.8 cells/uL

Primary: Annualized Relapse Rate (ARR) — 0.02 relapses per year

Primary: Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses — 0.109; 0.108 relapses per participant year — p=0.9758

Primary: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period — 0.350; 0.241; 0.181 relapses/year — p=<0.0001

Primary: Annualized Relapse Rate (ARR) at 1 Year — 0.397; 0.288; 0.256 relapses per person-years — p=0.0114

Primary: ARMS (Assessing Relapses in Multiple Sclerosis) ADL Scores (Activities of Daily Living) — 3.1; 4.9 score on a scale — p=0.003

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 17; 17; 24; 20 Participants

Primary: Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses — 0.122; 0.130 relapses per participant year — p=0.6691

Primary: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) Related to Study Drug During the Treatment Period — 59 Participants

Primary: Annualized Relapse Rate (ARR) — 0.04; 0.03 relapses per year

Primary: Safety and Tolerability — 10; 9; 10; 9 Participants with at least one TEAE

Primary: Time From Baseline to First Multiple Sclerosis Relapse (in Weeks) — 35.5; 40.9 weeks — p=0.1384

Primary: Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005) — 310; 182; 97 days — p=<0.001

Primary: Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio…

Primary: Change From Baseline in Patient-reported Treatment Satisfaction — 19.57; 5.83 score on a scale

Primary: Adjusted Annualized Relapse Rate (ARR) Based on Confirmed Relapses — 0.05 relapses per participant-year

Primary: Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab — -1232.97; -1169.13; -1008.13; -931.83 pg/mL

Primary: MRI Parameter- Percent Brain Volume Change for 2 Years — -0.862; -0.49 percent change per year

Primary: The Number of New or Recurrent Gd-enhancing Lesions That Appear on Brain T1-weighted MRI — 0.12 lesions

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001

Primary: Number of Participants Developing a New MS Relapse and/or MRI Brain Lesion Over the Course of the Study Duration — 6; 16 Participants — p=0.521

Primary: Number of Disease-free Patients — 5; 12 participants — p=0.0493

Primary: Annualized Relapse Rate (ARR) — 0.06 relapses/ participant-year — p=<0.0001